Vytrus Biotech S.A. Cash Flow Conversion Efficiency
Vytrus Biotech S.A. cash flow conversion efficiency. Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has a cash flow conversion efficiency ratio of 0.047x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€225.55K ≈ $263.69K USD) by net assets (€4.75 Million ≈ $5.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vytrus Biotech S.A. (2020–2025)
Cash flow conversion efficiency of Vytrus Biotech S.A. from 2020 to 2025. This chart illustrates how Vytrus Biotech S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View VYT stock price and chart for real-time trading data and today's change.
Vytrus Biotech S.A. Cash Flow Conversion Ratio Explained
Vytrus Biotech S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vytrus Biotech S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vytrus Biotech S.A. ranked by their cash flow conversion efficiency. Also see Vytrus Biotech S.A. stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stomil Sanok SA
WAR:SNK
|
0.014x |
|
CVC Ltd
AU:CVC
|
0.234x |
|
JINSUNG T.E.C. Inc
KQ:036890
|
-0.016x |
|
Punjab Chemicals & Crop Protection Limited
NSE:PUNJABCHEM
|
0.207x |
|
Selvas Ai Inc.
KQ:108860
|
0.009x |
|
T.K.S. Technologies Public Company Limited
BK:TKS
|
0.027x |
|
Zen Voce
TWO:3581
|
-0.017x |
|
Silver Pegasus Acquisition Corp.
NASDAQ:SPEG
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Vytrus Biotech S.A. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Vytrus Biotech S.A. from 2020 to 2025. Review Vytrus Biotech S.A. (VYT) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.31 Million ≈ $12.05 Million |
€3.90 Million ≈ $4.56 Million |
0.378x | +49.65% |
| 2024-12-31 | €7.29 Million ≈ $8.53 Million |
€1.84 Million ≈ $2.16 Million |
0.253x | +47.95% |
| 2023-12-31 | €5.29 Million ≈ $6.19 Million |
€904.39K ≈ $1.06 Million |
0.171x | +260.14% |
| 2022-12-31 | €4.75 Million ≈ $5.56 Million |
€225.55K ≈ $263.69K |
0.047x | -54.97% |
| 2021-12-31 | €4.25 Million ≈ $4.97 Million |
€447.92K ≈ $523.67K |
0.105x | +387.17% |
| 2020-12-31 | €3.61 Million ≈ $4.22 Million |
€-132.47K ≈ $-154.87K |
-0.037x | -- |
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more